Oncology Central

Metastatic castration-resistant prostate cancer: time for innovation


Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial responses, almost all patients progress to castration-resistant prostate cancer (CRPC). The understanding of the biology of CRPC and the evidence that CRPC still remains driven by androgen receptor signaling led to the discovery of new therapeutic targets.

To view restricted content, please:

Leave A Comment